Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan.
Clin Orthop Relat Res. 2023 Nov 1;481(11):2110-2124. doi: 10.1097/CORR.0000000000002720. Epub 2023 Jun 14.
BACKGROUND: Tumor-devitalized autografts treated with deep freezing, pasteurization, and irradiation are biological reconstruction methods after tumor excision for aggressive or malignant bone or soft tissue tumors that involve a major long bone. Tumor-devitalized autografts do not require a bone bank, they carry no risk of viral or bacterial disease transmission, they are associated with a smaller immunologic response, and they have a better shape and size match to the site in which they are implanted. However, they are associated with disadvantages as well; it is not possible to assess margins and tumor necrosis, the devitalized bone is not normal and has limited healing potential, and the biomechanical strength is decreased owing to processing and tumor-related bone loss. Because this technique is not used in many countries, there are few reports on the results of this procedure such as complications, graft survival, and limb function. QUESTIONS/PURPOSES: (1) What was the rate of complications such as fracture, nonunion, infection, or recurrence in a tumor-devitalized autograft treated with deep freezing, pasteurization, and irradiation, and what factors were associated with the complication? (2) What were the 5-year and 10-year grafted bone survival (free from graft bone removal) of the three methods used to devitalize a tumor-containing autograft, and what factors were associated with grafted bone survival? (3) What was the proportion of patients with union of the tumor-devitalized autograft and what factors were associated with union of the graft-host bone junction? (4) What was the limb function after the tumor-devitalized autograft, and what factors were related to favorable limb function? METHODS: This was a retrospective, multicenter, observational study that included data from 26 tertiary sarcoma centers affiliated with the Japanese Musculoskeletal Oncology Group. From January 1993 to December 2018, 494 patients with benign or malignant tumors of the long bones were treated with tumor-devitalized autografts (using deep freezing, pasteurization, or irradiation techniques). Patients who were treated with intercalary or composite (an osteoarticular autograft with a total joint arthroplasty) tumor-devitalized autografts and followed for at least 2 years were considered eligible for inclusion. Accordingly, 7% (37 of 494) of the patients were excluded because they died within 2 years; in 19% (96), an osteoarticular graft was used, and another 10% (51) were lost to follow-up or had incomplete datasets. We did not collect information on those who died or were lost to follow-up. Considering this, 63% of the patients (310 of 494) were included in the analysis. The median follow-up was 92 months (range 24 to 348 months), the median age was 27 years (range 4 to 84), and 48% (148 of 310) were female; freezing was performed for 47% (147) of patients, pasteurization for 29% (89), and irradiation for 24% (74). The primary endpoints of this study were the cumulative incidence rate of complications and the cumulative survival of grafted bone, assessed by the Kaplan-Meier method. We used the classification of complications and graft failures proposed by the International Society of Limb Salvage. Factors relating to complications and grafted autograft removal were analyzed. The secondary endpoints were the proportion of bony union and better limb function, evaluated by the Musculoskeletal Tumor Society score. Factors relating to bony union and limb function were also analyzed. Data were investigated in each center by a record review and transferred to Kanazawa University. RESULTS: The cumulative incidence rate of any complication was 42% at 5 years and 51% at 10 years. The most frequent complications were nonunion in 36 patients and infection in 34 patients. Long resection (≥ 15 cm) was associated with an increased risk of any complication based on the multivariate analyses (RR 1.8 [95% CI 1.3 to 2.5]; p < 0.01). There was no difference in the rate of complications among the three devitalizing methods. The cumulative graft survival rates were 87% at 5 years and 81% at 10 years. After controlling for potential confounding variables including sex, resection length, reconstruction type, procedure type, and chemotherapy, we found that long resection (≥ 15 cm) and composite reconstruction were associated with an increased risk of grafted autograft removal (RR 2.5 [95% CI 1.4 to 4.5]; p < 0.01 and RR 2.3 [95% CI 1.3 to 4.1]; p < 0.01). The pedicle freezing procedure showed better graft survival than the extracorporeal devitalizing procedures (94% versus 85% in 5 years; RR 3.1 [95% CI 1.1 to 9.0]; p = 0.03). No difference was observed in graft survival among the three devitalizing methods. Further, 78% (156 of 200 patients) of patients in the intercalary group and 87% (39 of 45 patients) of those in the composite group achieved primary union within 2 years. Male sex and the use of nonvascularized grafts were associated with an increased risk of nonunion (RR 2.8 [95% CI 1.3 to 6.1]; p < 0.01 and 0.28 [95% CI 0.1 to 1.0]; p = 0.04, respectively) in the intercalary group after controlling for confounding variables, including sex, site, chemotherapy, resection length, graft type, operation time, and fixation type. The median Musculoskeletal Tumor Society score was 83% (range 12% to 100%). After controlling for confounding variables including age, site, resection length, event occurrence, and graft removal, age younger than 40 years (RR 2.0 [95% CI 1.1 to 3.7]; p = 0.03), tibia (RR 6.9 [95% CI 2.7 to 17.5]; p < 0.01), femur (RR 4.8 [95% CI 1.9 to 11.7]; p < 0.01), no event (RR 2.2 [95% CI 1.1 to 4.5]; p = 0.03), and no graft removal (RR 2.9 [95% CI 1.2 to 7.3]; p = 0.03) were associated with an increased limb function. The composite graft was associated with decreased limb function (RR 0.4 [95% CI 0.2 to 0.7]; p < 0.01). CONCLUSION: This multicenter study revealed that frozen, irradiated, and pasteurized tumor-bearing autografts had similar rates of complications and graft survival and all resulted in similar limb function. The recurrence rate was 10%; however, no tumor recurred with the devitalized autograft. The pedicle freezing procedure reduces the osteotomy site, which may contribute to better graft survival. Furthermore, tumor-devitalized autografts had reasonable survival and favorable limb function, which are comparable to findings reported for bone allografts. Overall, tumor-devitalized autografts are a useful option for biological reconstruction and are suitable for osteoblastic tumors or osteolytic tumors without severe loss of mechanical bone strength. Tumor-devitalized autografts could be considered when obtaining allografts is difficult and when a patient is unwilling to have a tumor prosthesis and allograft for various reasons such as cost or socioreligious reasons. LEVEL OF EVIDENCE: Level III, therapeutic study.
背景:肿瘤灭活自体移植物经过深冷冻、巴氏消毒和照射处理,是用于切除侵袭性或恶性骨或软组织肿瘤后进行生物重建的方法,这些肿瘤涉及主要长骨。肿瘤灭活自体移植物不需要骨库,不存在病毒或细菌疾病传播的风险,免疫反应较小,并且形状和大小与植入部位更匹配。然而,它们也存在一些缺点;无法评估边缘和肿瘤坏死情况,灭活骨不正常,愈合潜力有限,并且生物力学强度因处理和肿瘤相关的骨丢失而降低。由于这种技术在许多国家没有使用,因此关于该手术的结果(如并发症、移植物存活率和肢体功能)的报道很少。
问题/目的:(1)深冷冻、巴氏消毒和照射处理的肿瘤灭活自体移植物的并发症发生率(如骨折、不愈合、感染或复发)是多少,哪些因素与并发症有关?(2)三种灭活肿瘤的自体移植物的 5 年和 10 年移植物存活率(无移植物骨去除)是多少,哪些因素与移植物存活率有关?(3)肿瘤灭活自体移植物的骨愈合率是多少,哪些因素与移植物-宿主骨结合有关?(4)肿瘤灭活自体移植物的肢体功能如何,哪些因素与良好的肢体功能有关?
方法:这是一项回顾性、多中心、观察性研究,包括来自日本肌肉骨骼肿瘤学组的 26 个三级肉瘤中心的数据。从 1993 年 1 月至 2018 年 12 月,对 494 例长骨良性或恶性肿瘤患者进行了肿瘤灭活自体移植物治疗(使用深冷冻、巴氏消毒或照射技术)。考虑纳入至少随访 2 年且接受节段性或复合(含全关节置换的骨-关节自体移植物)肿瘤灭活自体移植物治疗的患者。因此,由于 7%(37/494)的患者在 2 年内死亡而被排除在外;19%(96)使用了含关节的移植物,另有 10%(51)失访或数据集不完整。我们没有收集死亡或失访患者的信息。考虑到这一点,63%(310/494)的患者被纳入分析。中位随访时间为 92 个月(范围 24 至 348 个月),中位年龄为 27 岁(范围 4 至 84 岁),48%(148/310)为女性;47%(147)的患者行冷冻处理,29%(89)行巴氏消毒,24%(74)行照射。本研究的主要终点是并发症累积发生率和移植物存活率,通过 Kaplan-Meier 法评估。我们使用国际肢体挽救协会提出的并发症和移植物去除分类。分析与并发症和移植物去除有关的因素。次要终点是骨愈合率和更好的肢体功能,通过肌肉骨骼肿瘤协会评分评估。也分析了与骨愈合和肢体功能有关的因素。每个中心通过记录审查收集数据,并转移到金泽大学。
结果:任何并发症的累积发生率在 5 年时为 42%,在 10 年时为 51%。最常见的并发症是 36 例不愈合和 34 例感染。长切除(≥15 cm)与多因素分析中任何并发症的风险增加有关(RR 1.8[95%CI 1.3 至 2.5];p<0.01)。三种灭活方法之间的并发症发生率无差异。移植物存活率在 5 年时为 87%,在 10 年时为 81%。在控制性别、切除长度、重建类型、手术类型和化疗等潜在混杂变量后,我们发现长切除(≥15 cm)和复合重建与移植物去除的风险增加有关(RR 2.5[95%CI 1.4 至 4.5];p<0.01 和 RR 2.3[95%CI 1.3 至 4.1];p<0.01)。带蒂冷冻程序的移植物存活率优于体外灭活程序(5 年时分别为 94%和 85%;RR 3.1[95%CI 1.1 至 9.0];p=0.03)。三种灭活方法之间的移植物存活率无差异。此外,在节段性组中,156/200 例(78%)患者和在复合组中,39/45 例(87%)患者在 2 年内实现了原发性骨愈合。男性和使用非血管化移植物与不愈合的风险增加有关(RR 2.8[95%CI 1.3 至 6.1];p<0.01 和 0.28[95%CI 0.1 至 1.0];p=0.04,分别),在控制包括性别、部位、化疗、切除长度、移植物类型、手术时间和固定类型在内的混杂变量后,在节段性组中。肌肉骨骼肿瘤协会评分中位数为 83%(范围 12%至 100%)。在控制包括年龄、部位、切除长度、事件发生和移植物去除在内的混杂变量后,年龄小于 40 岁(RR 2.0[95%CI 1.1 至 3.7];p=0.03)、胫骨(RR 6.9[95%CI 2.7 至 17.5];p<0.01)、股骨(RR 4.8[95%CI 1.9 至 11.7];p<0.01)、无事件(RR 2.2[95%CI 1.1 至 4.5];p=0.03)和无移植物去除(RR 2.9[95%CI 1.2 至 7.3];p=0.03)与更好的肢体功能有关。复合移植物与较差的肢体功能有关(RR 0.4[95%CI 0.2 至 0.7];p<0.01)。
结论:这项多中心研究表明,冷冻、照射和巴氏消毒的含肿瘤自体移植物具有相似的并发症发生率和移植物存活率,且所有移植物均具有相似的肢体功能。复发率为 10%;然而,没有肿瘤在灭活的自体移植物中复发。带蒂冷冻程序减少了截骨部位,这可能有助于提高移植物存活率。此外,肿瘤灭活自体移植物具有合理的存活率和良好的肢体功能,与骨移植物的报告结果相当。总体而言,肿瘤灭活自体移植物是生物重建的一种有用选择,适用于成骨肿瘤或无严重机械骨强度丧失的溶骨肿瘤。在获得同种异体移植物困难和患者因各种原因(如费用或社会宗教原因)不愿意接受肿瘤假体和同种异体移植物时,可以考虑使用肿瘤灭活自体移植物。
证据水平:III 级,治疗性研究。
Cochrane Database Syst Rev. 2020-10-19